These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16676183)

  • 1. DC-based vaccine loaded with acid-eluted peptides in acute myeloid leukemia: the importance of choosing the best elution method.
    Delluc S; Tourneur L; Fradelizi D; Rubio MT; Marchiol-Fournigault C; Chiocchia G; Buzyn A
    Cancer Immunol Immunother; 2007 Jan; 56(1):1-12. PubMed ID: 16676183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous peptides eluted from acute myeloid leukemia cells can be used to generate specific antileukemic CD4 helper and CD8 cytotoxic T lymphocyte responses in vitro.
    Delluc S; Tourneur L; Michallet AS; Boix C; Varet B; Fradelizi D; Guillet JG; Buzyn A
    Haematologica; 2005 Aug; 90(8):1050-62. PubMed ID: 16079104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response.
    Delluc S; Hachem P; Rusakiewicz S; Gaston A; Marchiol-Fournigault C; Tourneur L; Babchia N; Fradelizi D; Regnault A; Sang KH; Chiocchia G; Buzyn A
    Cancer Immunol Immunother; 2009 Oct; 58(10):1669-77. PubMed ID: 19225777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination.
    Galea-Lauri J; Darling D; Mufti G; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2002 Aug; 51(6):299-310. PubMed ID: 12111118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge.
    Hermans IF; Daish A; Moroni-Rawson P; Ronchese F
    Cancer Immunol Immunother; 1997 Aug; 44(6):341-7. PubMed ID: 9298937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro stimulation of specific antileukemia T-cell response by dendritic cells derived from CD14+ acute monocytic leukemia cells].
    Sheng LX; Xie XB; Qiu GQ; Gu WY; Wang ZL; Wu HQ
    Ai Zheng; 2005 Nov; 24(11):1338-44. PubMed ID: 16552959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
    J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias.
    Charbonnier A; Gaugler B; Sainty D; Lafage-Pochitaloff M; Olive D
    Eur J Immunol; 1999 Aug; 29(8):2567-78. PubMed ID: 10458772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of the WT1
    Dagvadorj N; Deuretzbacher A; Weisenberger D; Baumeister E; Trebing J; Lang I; Köchel C; Kapp M; Kapp K; Beilhack A; Hünig T; Einsele H; Wajant H; Grigoleit GU
    Cancer Immunol Immunother; 2017 Mar; 66(3):319-332. PubMed ID: 27896368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells.
    Zeng Y; Graner MW; Thompson S; Marron M; Katsanis E
    Blood; 2005 Mar; 105(5):2016-22. PubMed ID: 15374884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.
    Paglia P; Chiodoni C; Rodolfo M; Colombo MP
    J Exp Med; 1996 Jan; 183(1):317-22. PubMed ID: 8551239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells.
    Draube A; Beyer M; Wolf J
    Eur J Haematol; 2008 Oct; 81(4):281-8. PubMed ID: 18573171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Experimental study on activating antileukemic T cells by vaccination with dendritic cells pulsed with survivin].
    Zhang XH; Xia LH; Liu ZP; Wei WN; Hu Y; Song SJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):66-9. PubMed ID: 12667293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Employing the immunological synapse in AML: development of leukemic dendritic cells for active specific immunization.
    Houtenbos I; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
    Immunobiology; 2005; 210(2-4):249-57. PubMed ID: 16164032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for dendritic cell-based vaccines for acute myeloid leukemia.
    Biragyn A
    Haematologica; 2005 Aug; 90(8):1010C. PubMed ID: 16079091
    [No Abstract]   [Full Text] [Related]  

  • 17. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods.
    Kremser A; Dressig J; Grabrucker C; Liepert A; Kroell T; Scholl N; Schmid C; Tischer J; Kufner S; Salih H; Kolb HJ; Schmetzer H
    J Immunother; 2010; 33(2):185-99. PubMed ID: 20139775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with leukemia-loaded dendritic cells eradicates residual disease and prevent relapse.
    Deeb D; Gao X; Jiang H; Divine G; Dulchavsky SA; Gautam SC
    J Exp Ther Oncol; 2006; 5(3):183-93. PubMed ID: 16528969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia.
    Subklewe M; Geiger C; Lichtenegger FS; Javorovic M; Kvalheim G; Schendel DJ; Bigalke I
    Cancer Immunol Immunother; 2014 Oct; 63(10):1093-103. PubMed ID: 25186611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.